The EXPECT RCT examines insulin Degludec (Tresiba) compared to insulin detemir (Levemir) in pregnant women with Type 1 Diabetes. The presentation will describe the rationale for the study. The trial is a multi-national, multi-center, randomized, open-label, parallel group, treat to target trial. Women were randomized to the trial either pregnant (8-14 weeks gestation) or in a pre-pregnancy phase and planning to become pregnant within 1 year of randomization. The study protocol was designed to demonstrate non inferiority of Degludec when compared to Detemir. The presentation will discuss the trial results of all pregnant women from both arms of the trial demonstrating non-inferiority and focusing on maternal efficacy and safety and neonatal outcomes.